FDA Clears First Human Trial for Novel Gene Therapy Targeting Fatal Genetic Heart Disease

WALTHAM, MA – February 04, 2026 – The U.S. Food and Drug Administration (FDA) has given the green light to Affinia Therapeutics to proceed with a clinical trial for AFTX-201, a pioneering gene therapy aimed at a rare and aggressive form of inherited heart failure. The acceptance of the company's Investigational New Drug (IND) application paves the way for the first human studies of a treatment that offers a new beacon of hope for patients with BAG3-associated dilated cardiomyopathy (DCM).

This regulatory milestone allows the Waltham-based biotechnology company to launch its Phase 1/2 clinical trial, named UPBEAT, in the coming weeks. The study will assess the safety and potential efficacy of what is designed to be a one-time intravenous treatment for a condition that currently has no cure and limited therapeutic options.

“We are grateful to the FDA for the timely review of our IND application for AFTX-201 for the treatment of BAG3-associated dilated cardiomyopathy and to the patient and clinician community who have provided valuable input and support for our investigational program to-date,” said Hideo Makimura, M.D., Ph.D., Chief Medical Officer at Affinia. “We look forward to initiating the UPBEAT clinical trial at multiple trial sites in the coming weeks and bringing a much-needed treatment option for patients and families affected by this devastating disease.”

The Devastating Toll of a Genetic Heart Defect

BAG3-associated dilated cardiomyopathy is a severe, chronic, and progressive illness caused by a mutation in the BAG3 gene. This gene is critical for producing a protein that helps maintain the normal structure and function of heart muscle cells. In its absence, the heart's chambers stretch, thin, and enlarge, impairing its ability to pump blood effectively. This leads to early-onset heart failure that progresses rapidly.

The condition affects more than 70,000 people across the United States, Europe, and Canada. While current standard-of-care treatments, such as medications and implantable devices, can help manage symptoms, they do not address the underlying genetic cause. The disease's relentless progression means that despite these interventions, nearly a quarter of all patients with BAG3 DCM will ultimately require a heart transplant to survive, highlighting a profound unmet medical need.

“BAG3 DCM is a genetic heart disease with significant medical need despite current standard of care,” said Matthew Wheeler, M.D., Ph.D., a physician scientist in genetic cardiomyopathies and Associate Professor in Cardiovascular Medicine at Stanford Medicine. “A gene therapy approach could make a real difference to patients living with BAG3 DCM.”

Engineering a Smarter, More Targeted Therapy

Affinia Therapeutics' AFTX-201 represents a significant leap forward in cardiac gene therapy. The treatment is designed to deliver a healthy, fully functional copy of the BAG3 gene directly to the heart's cells. The innovation lies not just in the gene replacement itself, but in the delivery vehicle.

AFTX-201 utilizes a proprietary, next-generation adeno-associated virus (AAV) capsid, which acts as a microscopic vehicle to transport the genetic payload. Affinia has engineered this capsid specifically for enhanced targeting of heart muscle, a long-standing challenge in the field. This precision allows the therapy to achieve effective cardiac delivery at doses that are five to ten times lower than those required by conventional AAV capsids, such as AAV9.

The implications of this lower dosing are significant. Higher doses of AAV gene therapies have been linked to potential safety concerns, including liver toxicity and immune system reactions. By reducing the required dose, AFTX-201 may offer an improved safety profile, potentially expanding the therapeutic window and making the treatment safer for patients.

Preclinical studies in animal models have been highly promising. The data showed that AFTX-201 not only increased the levels of functional BAG3 protein in the heart but also led to a complete restoration of cardiac function to normal levels. This outcome was not achieved when the same genetic payload was delivered using a conventional capsid, underscoring the potential superiority of Affinia's engineered delivery platform.

The UPBEAT Trial: Charting the Path Forward

The UPBEAT trial is a multicenter, open-label Phase 1/2 study designed to rigorously evaluate AFTX-201 in adults with a genetically confirmed diagnosis of BAG3 DCM. The primary goal of the study is to assess the therapy's safety and tolerability over a 52-week period following a single intravenous infusion. The trial will also measure pharmacodynamic and preliminary efficacy markers, such as changes in cardiac function from baseline.

The study will begin with a dose-exploration phase to identify an optimal dose, followed by a dose-expansion phase. The trial's design incorporates robust safety protocols, including predefined stopping rules and oversight by an independent Data Safety Monitoring Board, to ensure the utmost protection for participants.

This careful approach to clinical development, informed by input from patients, regulators, and clinicians, reflects the high stakes and immense potential of bringing a transformative therapy to a patient community with few options. For the thousands of families affected by BAG3 DCM, the initiation of this trial represents a tangible step forward in the long search for a meaningful treatment.